Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
CDMO is contracted to produce multiple clinical batches from German facility
Vibalogics has agreed to manufacture additional clinical trial material for the lead COVID-19 vaccine candidate of Johnson & Johnson’s vaccine unit, Janssen, the contract development and manufacturing organisation said on Monday.
In a statement, the firm said it was contracted to manufacture multiple batches from its GMP accredited facility in Cuxhaven, Germany, “which will result in many thousands of doses of an investigational COVID-19 vaccine candidate.”
“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” Stefan Beyer, managing director and CEO of Vibalogics said.
The CDMO, which offers process development, manufacturing, testing and fill-finish services, has recently invested in new equipment to handle larger clinical batches including a new filling line capable of filling and labelling more than 30,000 vials per batch.
In May 2019, Vibalogics was acquired by private equity firm Ampersand Capital Partners, with a remit to extend its US footprint. The CDMO said it is set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines “in the near future.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance